• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

    5/7/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email

    SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025.

    Sera Prognostics (PRNewsfoto/Sera Prognostics, Inc.)

    Recent Highlights:

    • Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrators.
    • Pursuing Medicaid opportunity, which represents approximately half of the market opportunity for Sera's PreTRM® Test; in discussions with several Medicaid plans across three states for PreTRM test implementation pilots.
    • Expecting to have strong presence at upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting May 16-18. Sera plans to meet with attendees to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm.
    • Appointed Jeff Elliott to Board of Directors, making talented board deeper with his breadth and depth of expertise in commercially scaling companies in our sector.

    "Following the results of our full PRIME pivotal study being publicized we are leveraging them by engaging with key plan providers in focused geographic regions hard hit by premature birth," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "While it will take some time to evolve, we anticipate that Medicaid providers in those areas will see the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test."

    First Quarter 2025 Financial Results

    First quarter 2025 revenue was $38,000 compared to nil for the same period of 2024.

    Total operating expenses were $9.3 million, compared with $9.1 million for the first quarter of 2024.

    Research and development expenses for the first quarter of 2025 were $3.3 million, and down approximately 9% compared with the first quarter of 2024 primarily due to lower clinical study costs as third-party expenses related to PRIME study analysis have continued to decrease.

    Selling, general and administrative expenses for the first quarter of 2025 were $5.9 million, up from $5.4 million for the prior-year period as we continue careful management of commercial activities targeted at driving future growth by adding strategic headcount, prepare for the publication of PRIME study data, invest in targeted awareness and other strategic initiatives.

    Net loss for the quarter was $8.2 million compared to $8.1 million for the prior-year quarter.

    As of March 31, 2025, the Company had cash, cash equivalents, and available-for-sale securities of approximately $114.2 million.

    Conference Call Information

    Sera Prognostics will host a corresponding conference call and live webcast today to discuss first quarter 2025 operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:

    US domestic callers: (800) 836-8184

    International callers: (646) 357-8785

    Webcast Registration Link: https://app.webinar.net/AgbMlY25y3q

    Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.

    About Sera Prognostics, Inc.

    Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.

    About Preterm Birth

    Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in the United States. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

    About the PreTRM® Test

    The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.

    Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company elevating engagement with payors and plan administrators; the Company's discussions with several Medicaid plans across three states for PreTRM test implementation pilots; the Company's plans to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm; Medicaid providers seeing the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test; the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. 

    Contact

    Investor Contact

    Peter DeNardo, CapComm Partners

    [email protected]

    +1 (415) 389-6400

    SERA PROGNOSTICS, INC.

    Condensed Statements of Operations

    (unaudited)

    (in thousands, except share and per share data)













    Three Months Ended







    March 31,







    2025





    2024



    Revenue



    $

    38





    $

    —



    Operating expenses:













    Cost of revenue





    40







    17



    Research and development





    3,334







    3,683



    Selling and marketing





    1,470







    1,227



    General and administrative





    4,444







    4,170



    Total operating expenses





    9,288







    9,097



    Loss from operations





    (9,250)







    (9,097)



    Interest expense





    (4)







    (9)



    Other income, net





    1,067







    1,009



    Net loss



    $

    (8,187)





    $

    (8,097)



    Net loss per share, basic and diluted



    $

    (0.20)





    $

    (0.25)



    Weighted-average shares outstanding, basic and diluted





    41,968,076







    32,220,038



     

    SERA PROGNOSTICS, INC.

    Condensed Balance Sheets

    (unaudited)

    (in thousands)



















    March 31,





    December 31,







    2025





    2024



    Assets













    Current assets:













    Cash and cash equivalents



    $

    5,230





    $

    4,043



    Marketable securities





    40,967







    42,193



    Accounts receivable





    25







    34



    Prepaid expenses and other current assets





    1,061







    1,330



    Total current assets





    47,283







    47,600



    Property and equipment, net





    1,312







    1,239



    Long-term marketable securities





    68,004







    21,973



    Intangible assets, net





    997







    1,026



    Other assets





    588







    737



    Total assets



    $

    118,184





    $

    72,575



    Liabilities and Stockholders' Equity













    Current liabilities:













    Accounts payable



    $

    1,207





    $

    1,969



    Accrued and other current liabilities





    1,892







    2,384



    Finance lease obligation, current portion





    81







    194



    Deferred revenue





    20,221







    20,223



    Total current liabilities





    23,401







    24,770



    Finance lease obligation, net of current portion





    —







    2



    Total liabilities





    23,401







    24,772



    Commitments and contingencies













    Stockholders' equity:













    Common stock, Class A and Class B





    4







    3



    Additional paid-in capital





    382,684







    327,534



    Accumulated other comprehensive income





    76







    60



    Accumulated deficit





    (287,981)







    (279,794)



    Total stockholders' equity





    94,783







    47,803



    Total liabilities and stockholders' equity



    $

    118,184





    $

    72,575



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-reports-first-quarter-2025-financial-results-302449108.html

    SOURCE Sera Prognostics, Inc.

    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Financials

    Live finance-specific insights

    See more
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    SEC Filings

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    See more

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care